Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01732627 · ClinicalTrials.gov registry record · Phase 2
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
NCT01732627 is a Phase 2 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 301 participants.
The verdict
NCT01732627, a Phase 2 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
Study Summary
Primary objectives: * To describe the antibody responses to meningococcal serogroups A, C, Y, and W 135, measured by serum bactericidal assay using human complement (hSBA) and baby rabbit complement (rSBA), induced by a single dose of Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein (MenACYW) Conjugate vaccine or Menomune® - A/C/Y/W 135. * To describe the safety profile of a single dose of MenACYW Conjugate vaccine or Menomune® - A/C/Y/W 135.
Interventions
- BIOLOGICAL Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine
- BIOLOGICAL Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2012-11-12 |
| Est. Completion | 2013-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01732627
The ClinicalTrials.gov registry entry for NCT01732627 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine is the first listed.
NCT01732627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01732627 about?
NCT01732627 is a clinical study titled "Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older". Primary objectives: * To describe the antibody responses to meningococcal serogroups A, C, Y, and W 135, measured by serum bactericidal assay using human complement (hSBA) and baby rabbit complement (rSBA), induced by a single dose of Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protei...
What is the current status of trial NCT01732627?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2012-11-12. Estimated completion is 2013-01-17.
What interventions are being tested in trial NCT01732627?
The interventions under investigation include: Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine (BIOLOGICAL), Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined (BIOLOGICAL).
Who is sponsoring clinical trial NCT01732627?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.